Want to see INSM full AI Analyst Report?

Insmed (INSM) Stock Forecast & Price Target

1,360 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INSM Analyst Ratings

Strong Buy

20 Buy

1 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Insmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INSM Stock 12 Month Forecast

Average Price Target

$196.42

▲(58.54% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $196.42 with a high forecast of $243.00 and a low forecast of $169.00. The average price target represents a 58.54% change from the last price of $123.89.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"97":"$97","244":"$244","133.75":"$133.8","170.5":"$170.5","207.25":"$207.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":243,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$243.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":196.42105263157893,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$196.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":169,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$169.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[97,133.75,170.5,207.25,244],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.59,118.92923076923077,129.26846153846154,139.6076923076923,149.94692307692307,160.28615384615384,170.62538461538463,180.9646153846154,191.30384615384617,201.64307692307693,211.9823076923077,222.32153846153847,232.66076923076923,{"y":243,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.59,115.34623481781377,122.10246963562753,128.8587044534413,135.61493927125505,142.37117408906883,149.12740890688258,155.88364372469636,162.6398785425101,169.39611336032388,176.15234817813763,182.9085829959514,189.66481781376518,{"y":196.42105263157893,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.59,113.23692307692308,117.88384615384615,122.53076923076924,127.17769230769231,131.82461538461538,136.47153846153847,141.11846153846153,145.76538461538462,150.4123076923077,155.05923076923077,159.70615384615385,164.3530769230769,{"y":169,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":147.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":211.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.51,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.59,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$243.00

Average Price Target$196.42

Lowest Price Target$169.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tiago Fauth

Raymond James

$187→$173

Buy

39.64%

Upside

Reiterated

10/20/26

Insmed price target lowered to $173 from $187 at Raymond JamesInsmed price target lowered to $173 from $187 at Raymond James

Adam Walsh

Roth MKM

$198

Buy

59.82%

Upside

Reiterated

10/20/26

Insmed (INSM) Gets a Buy from Roth MKM

Benjamin Burnett

Wells Fargo

$169

Buy

36.41%

Upside

Assigned

10/13/26

Wells Fargo Keeps Their Buy Rating on Insmed (INSM)

Andrew Fein

H.C. Wainwright

$220

Buy

77.58%

Upside

Reiterated

10/12/26

H.C. Wainwright Sticks to Their Buy Rating for Insmed (INSM)

Jason Zemansky

Bank of America Securities

$207

Buy

67.08%

Upside

Reiterated

10/12/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), DENTSPLY SIRONA (NASDAQ: XRAY) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

10/12/26

Insmed downgraded to Peer Perform from Outperform at Wolfe ResearchInsmed downgraded to Peer Perform from Outperform at Wolfe Research

Conor MacKay

BMO Capital

$192

Buy

54.98%

Upside

Reiterated

10/12/26

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Insmed (NASDAQ: INSM)

Maxwell Skor

Morgan Stanley

$218

Buy

75.96%

Upside

Reiterated

10/09/26

Insmed: Rising Brinsupri Scripts, Reaffirmed Guidance Support Buy Rating and Unchanged $218 Price Target

Leonid Timashev

RBC Capital

$195

Buy

57.40%

Upside

Reiterated

10/08/26

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

Ashwani Verma

UBS

$172

Buy

38.83%

Upside

Reiterated

10/07/26

Analysts' Top Healthcare Picks: Insmed (INSM), Bristol-Myers Squibb (BMY)

Graig Suvannavejh

Mizuho Securities

$195

Buy

57.40%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eliana Merle

Barclays

$237→$207

Buy

67.08%

Upside

Reiterated

09/30/26

Barclays Remains a Buy on Insmed (INSM)

Jessica Fye

J.P. Morgan

$175

Buy

41.25%

Upside

Reiterated

09/28/26

Wall Street Analysts Are Bullish on Top NA Picks

Andrea Newkirk

Goldman Sachs

$188

Buy

51.75%

Upside

Initiated

09/24/26

Wall Street Analysts Are Bullish on Top NA Picks

Danielle Brill

Truist Financial

$185→$195

Buy

57.40%

Upside

Reiterated

08/10/26

Truist Financial Remains a Buy on Insmed (INSM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tiago Fauth

Raymond James

$187→$173

Buy

39.64%

Upside

Reiterated

10/20/26

Insmed price target lowered to $173 from $187 at Raymond JamesInsmed price target lowered to $173 from $187 at Raymond James

Adam Walsh

Roth MKM

$198

Buy

59.82%

Upside

Reiterated

10/20/26

Insmed (INSM) Gets a Buy from Roth MKM

Benjamin Burnett

Wells Fargo

$169

Buy

36.41%

Upside

Assigned

10/13/26

Wells Fargo Keeps Their Buy Rating on Insmed (INSM)

Andrew Fein

H.C. Wainwright

$220

Buy

77.58%

Upside

Reiterated

10/12/26

H.C. Wainwright Sticks to Their Buy Rating for Insmed (INSM)

Jason Zemansky

Bank of America Securities

$207

Buy

67.08%

Upside

Reiterated

10/12/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), DENTSPLY SIRONA (NASDAQ: XRAY) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

10/12/26

Insmed downgraded to Peer Perform from Outperform at Wolfe ResearchInsmed downgraded to Peer Perform from Outperform at Wolfe Research

Conor MacKay

BMO Capital

$192

Buy

54.98%

Upside

Reiterated

10/12/26

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Insmed (NASDAQ: INSM)

Maxwell Skor

Morgan Stanley

$218

Buy

75.96%

Upside

Reiterated

10/09/26

Insmed: Rising Brinsupri Scripts, Reaffirmed Guidance Support Buy Rating and Unchanged $218 Price Target

Leonid Timashev

RBC Capital

$195

Buy

57.40%

Upside

Reiterated

10/08/26

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

Ashwani Verma

UBS

$172

Buy

38.83%

Upside

Reiterated

10/07/26

Analysts' Top Healthcare Picks: Insmed (INSM), Bristol-Myers Squibb (BMY)

Graig Suvannavejh

Mizuho Securities

$195

Buy

57.40%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eliana Merle

Barclays

$237→$207

Buy

67.08%

Upside

Reiterated

09/30/26

Barclays Remains a Buy on Insmed (INSM)

Jessica Fye

J.P. Morgan

$175

Buy

41.25%

Upside

Reiterated

09/28/26

Wall Street Analysts Are Bullish on Top NA Picks

Andrea Newkirk

Goldman Sachs

$188

Buy

51.75%

Upside

Initiated

09/24/26

Wall Street Analysts Are Bullish on Top NA Picks

Danielle Brill

Truist Financial

$185→$195

Buy

57.40%

Upside

Reiterated

08/10/26

Truist Financial Remains a Buy on Insmed (INSM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

OVIDOvid Therapeutics

OMCLOmnicell

IMUXImmunic

HITIHigh Tide

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months

Tiago FauthRaymond James

Success Rate

12/17 ratings generated profit

Average Return

+43.32%

Copying Tiago Fauth's trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +43.32% per trade.

1 Year

Tiago FauthRaymond James

Success Rate

14/17 ratings generated profit

Average Return

+81.88%

Copying Tiago Fauth's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +81.88% per trade.

2 Years

Tiago FauthRaymond James

Success Rate

12/17 ratings generated profit

Average Return

+174.58%

Copying Tiago Fauth's trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +174.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSM Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INSM has received 44 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. INSM average Analyst price target in the past 3 months is 196.42.

Each month's total comprises the sum of three months' worth of ratings.

INSM Financial Forecast

INSM Earnings Forecast

Next quarter’s earnings estimate for INSM is -$0.39 with a range of -$0.90 to -$0.09. The previous quarter’s EPS was -$0.06. INSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.

INSM Sales Forecast

Next quarter’s sales forecast for INSM is $499.06M with a range of $476.60M to $514.81M. The previous quarter’s sales results were $425.49M. INSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.

INSM Stock Forecast FAQ

What is INSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Insmed’s 12-month average price target is 196.42.

What is INSM’s upside potential, based on the analysts’ average price target?

Insmed has 58.54% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INSM a Buy, Sell or Hold?

Insmed has a consensus rating of Strong Buy which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings.

What is Insmed’s price target?

The average price target for Insmed is 196.42. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $243.00 ,the lowest forecast is $169.00. The average price target represents 58.54% Increase from the current price of $123.89.

What do analysts say about Insmed?

Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of INSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Insmed (INSM) Stock Forecast & Price Target

INSM Analyst Ratings

INSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insmed

INSM Analyst Recommendation Trends

INSM Financial Forecast

INSM Earnings Forecast

INSM Sales Forecast

INSM Stock Forecast FAQ

Detailed List of Analyst Forecasts